KR930019225A - 제암방법 및 제암제 - Google Patents

제암방법 및 제암제 Download PDF

Info

Publication number
KR930019225A
KR930019225A KR1019930003358A KR930003358A KR930019225A KR 930019225 A KR930019225 A KR 930019225A KR 1019930003358 A KR1019930003358 A KR 1019930003358A KR 930003358 A KR930003358 A KR 930003358A KR 930019225 A KR930019225 A KR 930019225A
Authority
KR
South Korea
Prior art keywords
anticancer
antigen
histocompatibility class
cancer
agent
Prior art date
Application number
KR1019930003358A
Other languages
English (en)
Inventor
고우지 에가와
이찌에이 사또
Original Assignee
사토이찌에이
바이오 디펜스 인스티튜트 캄파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사토이찌에이, 바이오 디펜스 인스티튜트 캄파니 리미티드 filed Critical 사토이찌에이
Publication of KR930019225A publication Critical patent/KR930019225A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

암세포 표면에 표현된 암항원에 대해 특이적인 면역반응을 사용한 제암방법 및 제암제가 제공된다. 인간비교전적 조직적합 클라스 1항원, 이 항원을 인식하는 항체, 또는 장해성 임파구가 면역요법으로 암환자에 투여되어 암에 대한 저항력을 갖게한다.

Description

제암방법 및 제암제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 H-2K마우스로부터 유도된 암세포계에서 Qa-2항원의 존재를 나타내는 그라프도.
제2도는 항 Qa-2모노크로날 항체(mAb) 및 급단백질 용액 크로마토그라피 (FPLC) 정제품의 보체의존세포 장해활성시험결과를 나타낸 그라프도.
제3도는125I로 표시한 FPLC 정제품의 오토래디오그라피 분석 결과를 나타낸 도면.

Claims (6)

  1. 비교전적 조직적합 클라스 1항원을 투여하는 것을 특징으로한 제암방법.
  2. 비교전적 조직적합 클라스 1항원을 인식하는 항체를 투여하는 것을 특징으로 한 제암방법.
  3. 비교전적 조직적합 클라스 1항원을 인식하는 장해성 임파구를 투여하는 것을 특징으로 한 제암방법.
  4. 유효성분으로 비고전적 조직적합 클라스 1항원을 포함하는 것을 특징으로 한 제암제.
  5. 비고전적 조직적합 클라스 1항원을 인식하는 항체를 유효성분으로 포함하는 것을 특징으로 한 제암제.
  6. 비고전적 조직적합 클라스 1항원을 인식하는 장해성 임파구를 유효성분으로 포함하는 것을 특징으로 한 제암제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019930003358A 1992-03-05 1993-03-05 제암방법 및 제암제 KR930019225A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4048840A JPH05246889A (ja) 1992-03-05 1992-03-05 制癌方法および制癌剤
JP4-48840 1992-03-05

Publications (1)

Publication Number Publication Date
KR930019225A true KR930019225A (ko) 1993-10-18

Family

ID=12814449

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930003358A KR930019225A (ko) 1992-03-05 1993-03-05 제암방법 및 제암제

Country Status (15)

Country Link
EP (1) EP0563627A2 (ko)
JP (1) JPH05246889A (ko)
KR (1) KR930019225A (ko)
CN (1) CN1079400A (ko)
AU (1) AU3398793A (ko)
BR (1) BR9300764A (ko)
CA (1) CA2090957A1 (ko)
CZ (1) CZ34293A3 (ko)
FI (1) FI930976A (ko)
HU (1) HUT67859A (ko)
IL (1) IL104944A0 (ko)
NO (1) NO930798L (ko)
NZ (1) NZ247057A (ko)
SK (1) SK15993A3 (ko)
ZA (1) ZA931558B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
IT1274592B (it) * 1994-08-05 1997-07-18 Angela Turiano Composizione farmaceutica per la terapia tumorale contenente xenoantigeni
EP0937258A2 (en) * 1996-10-29 1999-08-25 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
EP1054688B1 (fr) * 1998-02-20 2004-06-30 Commissariat A L'energie Atomique Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
FR2775189B1 (fr) * 1998-07-24 2001-06-08 Commissariat Energie Atomique Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
EP1245675A1 (en) * 2001-03-28 2002-10-02 Kohji Egawa Cancer cell-specific HLA-F antigen and a diagnostic method of cancer by using thereof
WO2004078137A2 (en) * 2003-03-04 2004-09-16 Greenville Hospital System Antitumor agents comprising a targeting portion and an immune response triggering portion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung

Also Published As

Publication number Publication date
EP0563627A2 (en) 1993-10-06
CN1079400A (zh) 1993-12-15
BR9300764A (pt) 1993-09-28
JPH05246889A (ja) 1993-09-24
FI930976A0 (fi) 1993-03-04
NO930798L (no) 1993-09-06
CA2090957A1 (en) 1993-09-06
HU9300612D0 (en) 1993-05-28
NZ247057A (en) 1995-10-26
IL104944A0 (en) 1993-07-08
NO930798D0 (no) 1993-03-04
EP0563627A3 (ko) 1994-04-27
ZA931558B (en) 1993-09-27
AU3398793A (en) 1993-09-09
SK15993A3 (en) 1993-10-06
HUT67859A (en) 1995-03-23
CZ34293A3 (en) 1994-01-19
FI930976A (fi) 1993-09-06

Similar Documents

Publication Publication Date Title
Lehner et al. Association between HLA-DR antigens and helper cell activity in the control of dental caries
Mehra et al. Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid
Hviid et al. Perturbation and proinflammatory type activation of Vδ1+ γδ T cells in African children with Plasmodium falciparum malaria
Kiessling et al. Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems.
Nakamura et al. Effect of IFN-γ on the immune response in vivo and on gene expression in vitro
Mond et al. Recombinant interferon-gamma inhibits the B cell proliferative response stimulated by soluble but not by Sepharose-bound anti-immunoglobulin antibody.
Gery et al. Potentiation of the T-lymphocyte response to mitogens: II. the cellular source of potentiating mediator (s)
Katz et al. Cell interactions between histoincompatible t and b lymphocytes: ii. failure of physiologic cooperative interactions between t and b lymphocytes from allogeneic donor strains in humoral response to hapten-protein conjugates
Handman et al. Stage-specific, strain-specific, and cross-reactive antigens of Leishmania species identified by monoclonal antibodies
Gorczynski et al. Nonspecific and specific immuno-suppression in tumour-bearing mice by soluble immune complexes
Griffiths et al. The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum
DE69232782D1 (de) Zielgerichtetes Einbringen eines Virus-Vektors in Säugetierzellen.
FI924082A (fi) Idiotypvaccination mot b-cellymfoma
KR930019225A (ko) 제암방법 및 제암제
AU621830B2 (en) Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
FI932912A (fi) Testmetod och reagensfoerpackning avsedd foer den
Asherson et al. Inhibitory T cells
Shirakawa et al. Immunosuppressive factors from adult T-cell leukemia cells
Attallah et al. Differential effects of interferon on the MHC expression of human lymphocytes: enhanced expression of HLA without effect on Ia
NO922621D0 (no) Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav
Stutman et al. Normal levels of natural cytotoxic cells against solid tumours in NK-deficient beige mice
Basten et al. Role of Macrophages in T Cell–B Cell Collaboration in Antibody Production
Henney et al. Natural killer cells. In vitro and in vivo.
Damle et al. Activation of antigen-specific suppressor T lymphocytes in man involves dual recognition of self class I MHC molecules and Leu-4/T3-associated structures on the surface of inducer T lymphocytes.
Sopori et al. Differential requirement for accessory cells in polyclonal T-cell activation

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid